LIAN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.59%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

LianBio Insider Trading History Chart

LianBio Share Price & Price History

^$0.30

▲ +0.02 (7.19%)

As of 04/25/2024 01:00 AM ET

Days: 30 | 90 | 365

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

LianBio Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/18/2022	Perceptive Advisors Llc	Director	Buy	998,240	$2.40	$2,395,776.00	3,728,491
5/25/2022	Perceptive Advisors Llc	Director	Buy	120,000	$2.63	$315,600.00	2,661,251
5/23/2022	Perceptive Advisors Llc	Director	Buy	8,700	$2.49	$21,663.00	2,498,700

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

SEC Filings (Institutional Ownership Changes) for LianBio (NASDAQ:LIAN)

74.85% of LianBio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

LianBio Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/13/2024	Affinity Asset Advisors LLC	3,779,694	$16.90M	3.1%	+462.2%	3.498%
2/6/2024	Axxcess Wealth Management LLC	27,126	$0.12M	0.0%	+63.5%	0.025%
1/19/2024	Donald L. Hagan LLC	20,600	$92K	0.1%	+37.3%	0.019%
12/6/2023	Citigroup Inc.	615,940	$0.92M	0.0%	-12.9%	0.570%
11/15/2023	Axxcess Wealth Management LLC	16,590	$25K	0.0%	N/A	0.015%
11/15/2023	Affinity Asset Advisors LLC	672,357	$1M	0.3%	-16.0%	0.627%
11/14/2023	22NW LP	2,211,678	$3.30M	2.3%	+1,466.1%	2.064%
11/13/2023	Acadian Asset Management LLC	181,144	$0.27M	0.0%	+27.3%	0.169%
11/9/2023	Citigroup Inc.	615,940	$0.92M	0.0%	-12.9%	0.575%
11/8/2023	Landscape Capital Management L.L.C.	131,641	$0.20M	0.0%	N/A	0.123%
10/27/2023	TD Asset Management Inc	357,038	$0.53M	0.0%	+100.0%	0.333%
9/21/2023	Barclays PLC	22,297	$51K	0.0%	-64.2%	0.021%
8/21/2023	Affinity Asset Advisors LLC	800,676	$1.83M	0.6%	+23.2%	0.747%
8/11/2023	MYDA Advisors LLC	137,851	$0.31M	0.1%	+14.9%	0.129%
8/10/2023	Citigroup Inc.	707,336	$1.61M	0.0%	-2.3%	0.660%
8/7/2023	Acadian Asset Management LLC	142,336	$0.32M	0.0%	N/A	0.133%
7/27/2023	Virtu Financial LLC	10,848	$25K	0.0%	N/A	0.010%
7/20/2023	Exchange Traded Concepts LLC	27,778	$63K	0.0%	N/A	0.026%
7/17/2023	Donald L. Hagan LLC	15,000	$34K	0.0%	N/A	0.014%
7/10/2023	SG Americas Securities LLC	58,541	$0.13M	0.0%	N/A	0.055%
5/15/2023	MYDA Advisors LLC	120,000	$0.24M	0.1%	-11.1%	0.112%
2/15/2023	Tang Capital Management LLC	59,600	$98K	0.0%	N/A	0.055%
2/14/2023	VR Adviser LLC	4,793,047	$7.86M	1.3%	-10.9%	4.424%
2/13/2023	Cornercap Investment Counsel Inc.	165,718	$0.27M	0.0%	+102.5%	0.153%
11/15/2022	Tybourne Capital Management HK Ltd.	3,303,573	$6.61M	0.6%	-0.3%	3.049%
11/15/2022	Perceptive Advisors LLC	57,558,451	$115.12M	3.3%	+1.8%	53.121%
11/15/2022	Logos Global Management LP	307,908	$0.62M	0.1%	-21.9%	0.284%
11/14/2022	Powell Investment Advisors LLC	30,000	$60K	0.0%	N/A	0.028%
11/7/2022	TD Asset Management Inc.	178,519	$0.36M	0.0%	+15.2%	0.165%
11/3/2022	The Manufacturers Life Insurance Company	117,484	$0.24M	0.0%	+51.0%	0.108%
11/3/2022	Barclays PLC	268,400	$0.54M	0.0%	N/A	0.248%
10/18/2022	Bailard Inc.	19,606	$39K	0.0%	-58.8%	0.018%
8/12/2022	Affinity Asset Advisors LLC	450,000	$0.97M	0.4%	+38.5%	0.416%
8/11/2022	Alps Advisors Inc.	64,228	$0.14M	0.0%	-41.7%	0.059%
7/27/2022	Bailard Inc.	47,597	$0.10M	0.0%	+29.0%	0.044%
4/25/2022	Bailard Inc.	36,900	$0.14M	0.0%	N/A	0.034%
2/25/2022	Tybourne Capital Management HK Ltd.	3,314,173	$20.42M	0.6%	N/A	3.090%
2/15/2022	Laurion Capital Management LP	200,000	$1.23M	0.0%	N/A	0.186%
2/14/2022	Deerfield Management Company L.P. Series C	1,782,747	$10.98M	0.2%	N/A	1.662%
2/14/2022	Perceptive Advisors LLC	56,319,960	$346.93M	5.4%	N/A	52.518%
2/14/2022	Point72 Hong Kong Ltd	19,957	$0.12M	0.0%	N/A	0.019%
2/14/2022	Schf GPE LLC	937,500	$5.78M	1.0%	N/A	0.874%
2/14/2022	Ghisallo Capital Management LLC	100,000	$0.62M	0.0%	N/A	0.093%
2/14/2022	Alliancebernstein L.P.	3,204,730	$19.74M	0.0%	N/A	2.988%
2/14/2022	Casdin Capital LLC	206,415	$1.27M	0.0%	N/A	0.192%
2/14/2022	Affinity Asset Advisors LLC	72,406	$0.45M	0.2%	N/A	0.068%
2/11/2022	CNA Financial Corp	15,993	$99K	0.0%	N/A	0.015%
2/11/2022	Pentwater Capital Management LP	110,000	$0.68M	0.0%	N/A	0.103%
2/11/2022	MYDA Advisors LLC	20,000	$0.12M	0.0%	N/A	0.019%
2/10/2022	Vida Ventures Advisors LLC	2,282,084	$14.06M	5.3%	N/A	2.128%
2/10/2022	TD Asset Management Inc.	154,919	$0.95M	0.0%	N/A	0.144%
2/9/2022	Element Capital Management LLC	20,157	$0.12M	0.0%	N/A	0.019%
2/9/2022	Alps Advisors Inc.	121,816	$0.75M	0.0%	N/A	0.114%
2/7/2022	Victory Capital Management Inc.	173,460	$1.07M	0.0%	N/A	0.162%

Data available starting January 2016

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $0.30

$0.28

$0.30

50 Day Range

MA: $2.22

$0.28

$4.99

52 Week Range

Now: $0.30

$0.27

$4.99

Volume

5,242 shs

Average Volume

1,037,083 shs

Market Capitalization

$32.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Who are the company insiders with the largest holdings of LianBio?: LianBio's top insider shareholders include:
Perceptive Advisors Llc (Director)
Learn More about top insider investors at LianBio.